Breakthrough: Hengrui Pharmaceutical's Innovative Drug Revenue Surpasses ￥10 Billion!

Hengrui Pharmaceutical, a leading pharmaceutical company, has achieved a remarkable milestone as its revenue from innovative drugs surpasses 10 billion yuan. This achievement highlights the company's commitment to research and development, as well as its success in commercializing novel therapies. 

Hengrui Pharmaceutical recently released its annual report for 2023 and the first quarter of 2024, revealing impressive financial results. In 2023, the company's total operating revenue reached 22.82 billion yuan, representing a year-on-year growth of 7.26%. Notably, the revenue from innovative drugs accounted for 46.6% of the total, amounting to 10.637 billion yuan—a substantial increase of 22.1%.

The company's net profit attributable to shareholders also witnessed substantial growth. With a net profit of 4.302 billion yuan, an increase of 10.14% compared to the previous year, Hengrui Pharmaceutical has demonstrated its financial strength and stability. Furthermore, the net profit, excluding non-recurring gains and losses, amounted to 4.141 billion yuan, reflecting a significant growth rate of 21.46%.

Hengrui Pharmaceutical's success can be attributed to its strategic focus on innovation and research. Despite the challenges faced by the generic drug segment due to centralized procurement policies, the company's investments in innovative drugs have paid off handsomely. With over 16 innovative drugs already on the market, including self-developed and imported products, Hengrui Pharmaceutical has established itself as a key player in the pharmaceutical industry.

One of the notable areas of focus for Hengrui Pharmaceutical is antibody-drug conjugates (ADCs). ADCs, considered the next generation of anti-tumor drugs, have garnered significant attention within the industry. Leveraging its expertise and a modular HRMAP technology platform developed over a decade, Hengrui Pharmaceutical has successfully obtained clinical approval for 11 differentiated ADC molecules. These include HER2 ADC product SHR-A1811, TROP2 ADC product SHR-A1921, and Claudin 18.2 ADC product SHR-A1904, which have entered phase III clinical trials.

Looking ahead, Hengrui Pharmaceutical's investment in innovation and the commercialization of novel drugs is expected to drive future revenue growth. With an extensive pipeline of more than 90 innovative products in clinical development and nearly 300 clinical trials conducted globally, the company is poised for further success. Key therapeutic targets such as HER2, TROP2, Claudin18.2, and HER3, among others, ensure Hengrui Pharmaceutical's presence in high-demand areas.

Hengrui Pharmaceutical's achievement of surpassing 10 billion yuan in revenue from innovative drugs marks a significant milestone in the company's history. Through its unwavering commitment to research and development, strategic focus on innovation, and successful commercialization of novel therapies, Hengrui Pharmaceutical has emerged as a prominent player in the pharmaceutical industry. With a robust pipeline and a strong financial performance, the company is well-positioned for future growth and continued contributions to the advancement of healthcare.